Latest Therapeutics News

Page 19 of 90
Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.
Ada Torres
Ada Torres
11 June 2026
Argenica has completed the last FDA-mandated cardiac safety assay for its stroke drug ARG-007, paving the way to lift the clinical hold and initiate Phase 2b trials in the US.
Ada Torres
Ada Torres
11 June 2026
Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.
Ada Torres
Ada Torres
10 June 2026
Imugene’s off-the-shelf CAR T therapy azer-cel has won FDA Fast Track Designation for relapsed or refractory CLL/SLL and MZL, backed by compelling Phase 1b response rates.
Ada Torres
Ada Torres
9 June 2026
Resonance Health is progressing its MRI Liver Fibrosis device through late-stage clinical validation, targeting FDA biomarker qualification, while maintaining a profitable SaaMD platform and forecasting $16 million revenue for FY26.
Ada Torres
Ada Torres
9 June 2026
Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.
Ada Torres
Ada Torres
9 June 2026
Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.
Ada Torres
Ada Torres
3 June 2026
Opthea Limited resumes ASX trading as it pivots to develop OPT-302 for lymphangioleiomyomatosis, outlining a disciplined 18-month staged clinical program backed by A$31.2 million in cash.
Ada Torres
Ada Torres
3 June 2026
Entropy Neurodynamics has successfully dosed all six participants in the first cohort of its Phase 2 trial for TRP-8803, an intravenous psilocin therapy targeting Binge Eating Disorder. The study demonstrated controlled psychedelic responses, setting the stage for a Data and Safety Monitoring Board review and topline results expected in July 2026.
Ada Torres
Ada Torres
2 June 2026
Chimeric Therapeutics reports encouraging Phase 1/2 data for its CHM CDH17 CAR-T therapy in advanced gastrointestinal cancers, with 82% of evaluable patients achieving stable disease and durable responses lasting over a year.
Ada Torres
Ada Torres
1 June 2026
Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.
Ada Torres
Ada Torres
29 May 2026
Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.
Ada Torres
Ada Torres
29 May 2026

Browse the archive

Full archive